Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
life sciences
national blog main
startups
national top stories
new york blog main
new york top stories
venture capital
20/20 healthcare partners
amgen ventures
amyotrophic lateral sclerosis
anthony despasqua
antisense oligonucleotide
azacitidine
benzodiazepines
beta-thalassemia
biogen
blackstone group
blackstone life sciences
christian angermayer
clinical trials
columbia university
dacogen
david goldstein
deals
decitabine
depression
dna
dolby family ventures
enclear therapies
epi4k
epigenetics
epilepsy
epizyme
essential tremor
farydak
financing
What
drugs
3
×
new
3
×
aims
medicines
neuro
research
approach
associated
backed
based
biotech
called
cause
ceo
companies
debuts
develop
developing
device
dialysis
disease
diseases
enclear
epigenetic
epigenetics
epilepsy
field
flagship’s
genes
genetic
harmful
links
marcio
morning
mutations
nets
neurodegenerative
omega
praxis
precision
Language
unset
Current search:
boston
×
new
×
drugs
×
@xconomy.com
3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further